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Introduction
Acute myeloid leukemia (AML) is the most prevalent 
acute leukemia in adults encompassing 80% of cases 
of this group.1 It is a malignancy characterized by the 
abnormal differentiation and proliferation of myeloid 
stem cells clonal population.2 Some special chromosomal 
alterations can lead to the formation of chimeric proteins 
which in turn may increase the likelihood of malignant 
transformation.3
AML is a heterogeneous disease with possessing 
different cytogenetic and molecular features which are 
considered as the key prognostic factors predicting 
the risk of survival and relapse.3 Recent advances in 
treatment protocols are based on these prognostic factors 
contributing to individualized therapy and risk-adapted 
intensification.4 
The Wilms tumor 1 (WT-1) locus in chromosomal 
region 11p13; encodes a transcription factor highly 
expressed in the cells of the majority of leukemia patients at 
diagnosis, and apparently participates in leukemogenesis.5 
High expression of WT-1 in acute leukemia has been 
reported to represent a molecular marker of malignant 
hematopoiesis and was associated with fewer remissions 
and poor overall survival.6,7
Another molecular change in AML is the deregulated 
expression of brain and acute leukemia-cytoplasmic 
(BAALC) gene. BAALC, which maps on chromosome 8 at 
8q22.3, is involved in neuroectodermal and hematopoietic 
development.8 The expression of BAALC was reported 
as a precursor for hematopoiesis like the cluster of 
differentiation CD34+ in early hematopoietic cells.9 High 
expression of that was found in bone marrow of AML 
patients with a normal karyotype10 and identified as an 
independent poor prognostic indicator, associated with 
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Purpose: Acute myeloid leukemia (AML) is the most prevalent acute leukemia in adults. It 
possesses different cytogenetic and molecular features. The expression of Wilms tumor-1 (WT-
1), brain and acute leukemia, cytoplasmic (BAALC) and ETS-related gene (ERG) might be 
considered as prognostic factors in AML patients. The aim of this study was to determine the 
mRNA expressions of WT-1, BAALC and ERG genes in bone marrow of mononuclear cells and 
their effects on complete remission in the Iranian AML patients, pre- and post- chemotherapy.
Methods: Forty AML patients with normal karyotype were evaluated. The mRNA gene expressions 
were measured with quantitative real-time PCR in bone marrow of mononuclear cells of AML 
patients at the baseline and after chemotherapy. The subtypes of AML and flow cytometry panel 
were also assessed. Complete remission (CR) after the treatment was addressed for all patients.
Results: The mRNA expressions of WT-1, BAALC and ERG were significantly decreased after 
the treatment (p= 0.001, 0.017, 0.036). WT-1 mRNA expression was inversely correlated with 
CR after chemotherapy (P =0.024). There was also significant correlation between baseline 
expression of BAALC and CR (P=0.046). No significant correlation was observed between 
ERG and CR pre- and post- chemotherapy (P =0.464 and 0.781). There was also significant 
correlation between BAALC mRNA expression and CD34+ (P <0.001).
Conclusion: The present study showed that WT-1 decreased significantly after standard 
chemotherapy which could have favorable effects on CR. Also, the high expression of BAALC 
could have a poor prognostic role in AML patients. The identification of these gene expressions 
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shorter survival.11 
No specific role was explained for BAALC in 
leukemogenesis, but it was suggested that it blocks 
myeloid differentiation.12 It was suggested that high 
expression of BAALC is associated with a poor outcome 
in AML patients.13 Moreover, ETS-related gene (ERG) 
located on chromosome band 21q22, is a transcription 
factor required for normal hematopoiesis.14 The elevated 
expression of ERG was demonstrated in cytogenetically 
normal AML patients and has a negative role in the 
prognosis of AML.15,16 The role of standard treatment in 
the expression of these genes as well as the effect of post- 
treatment molecular changes on complete remission (CR) 
are not clearly investigated in the Iranian population. 
In a study in North-East of Iran, the overexpression of 
BAALC was observed in AML patients aged 2 to 77. The 
up-regulation of BAALC was reported with survivability 
reduction.17 In another study, high level of BAALC in 
pediatric AML patients was associated with lower overall 
survival rate.18 High expression of WT-1 was also shown 
in a study on Iranian AML patients.19 However, no study 
was conducted to evaluate these genes expression in AML 
at pre- and post-treatment phases. 
Therefore, this study was designed to assess the 
expression of WT-1, BAALC, and ERG in normal 
karyotype of de novo AML patients and to compare the 




The study was performed on 40 normal karyotype de novo 
AML patients referred to Shahid Ghazi Tabatabai hospital 
in Tabriz, the Oncology and Hematology center in North-
West of Iran, throughout the period between October 2018 
and October 2019. The diagnosis of AML was confirmed 
by morphology and flow cytometry of bone marrow 
samples. Cytogenetic screening was also performed to 
select the normal karyotype patients. Patients’ karyotype 
was analyzed based on bone marrow of leukemic cells 
metaphases. Furthermore, AML subtypes were addressed 
based on French–American–British classification. The 
patients aged > 18 with diagnosis of AML were included 
in the study. Patients with other types of cancer or 
with secondary AML were excluded. All patients were 
undergone standard induction therapy according to 
7-3 protocol (7 days with Cytarabine and 3 days with 
Daunorubicin or idarubicin). The second bone marrow 
sampling was done 2 weeks after the last chemotherapy. 
CR was assessed based on blast count less than 5%. 
Laboratory analysis 
Flow cytometry analysis 
Bone marrow samples were collected at diagnosis. The 
volume of bone marrow samples were 5 to 10 ml and 
collected on sterile ethylenediaminetetraacetic acid 
(EDTA) tube. For immunophenotyping analysis BD FACS 
Calibur (Becton, Dickinson Fluorescence Activated Cell 
Sorter (Becton, Dickinson Company, CA, USA) was used. 
The CD markers for Acute Leukemia Panel were: TdT, 
cy MPO, HLA-DR, GLYCO A, CD2, CD3, CD7, CD10, 
CD11b, CD13, CD14, CD15, CD19, CD20, CD22, CD33, 
CD34, CD38, CD41, CD45, CD61, CD117. 
RNA extraction and cDNA synthesis 
First, mononuclear cells were centrifuged by Ficoll-
Hypaque density gradient. Total RNA extraction 
from mononuclear cells and blasts was done using 
Trizol Reagent (Invitrogen, USA) according to the 
manufacturer’s instructions. Total RNA (1 μg) was used 
for cDNAs synthesis with RevertAid™ H Minus Reverse 
Transcriptase (RT) (200U), primers (10 μM), dNTPs (1 
mM), and RiboLock RNase inhibitor (20 U). The process 
was conducted at diagnosis and after chemotherapy. 
Quantitative real-time PCR
The gene expressions of WT-1, BAALC, and ERG were 
analyzed by quantitative Real-Time PCR at diagnosis and 
after chemotherapy by Life Science System (Rotor-Gene 
6000). cDNA was diluted by 4-fold, then 2 μL was used in 
each PCR reaction with the volume of 15μL. It contained 
150 nM of primers and 1X FastStart SYBR Green Master 
(Roche). Sequences of primers are listed in Table 1. The 
expression levels of β-Actin (ACTB), as a reference gene, 
were used to calculate relative expression levels. Data were 
shown as a ratio of the target gene/ACTB. The relative 
quantification (RQ) was performed by 2(-ΔΔCt): expression 
of target genes / β-actin Treated / Untreated = (1+E) -Ct target 
gene / (1+E) -Ct β-actin Treated / (1+E) -Ct target gene / (1+E) -Ct β-actin 
Untreated.
Standard curve
A standard curve was used to determine the efficiency of 
RT-PCR reactions. To perform the curve, a positive PCR 
product was diluted serially by 10-fold. The logarithmic of 
concentrations of customary RT-PCR were plotted against 
the target gene cycling threshold (Ct) of serial dilution. 
The efficiencies of WT-1, BAALC, ERG and β-Actin were 
96%, 93%, 97% and 96%, respectively.
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Statistical analysis 
For statistical analyses the SPSS software (ver. 21; IBM 
Corp., Armonk, NY, USA) was used; the significance 
of p-values was considered less than 0.05. Normality 
of data distribution was checked based on descriptive 
status. Normal-distributed data were expressed as mean 
± SD, and non-parametric data were shown as median 
(75%, 25%). For possible difference in gene expression 
pre- and post-chemotherapy, Wilcoxon-signed rank test 
was utilized. The association between gene expression 
and other variables were performed using Spearman 
correlation-coefficient test. The differences between non-
parametric variables were checked by chi-square test. 
Results
Patients 
In the present study, 40 de novo AML patients were 
studied. The mean ± SD age of the patients was 36.75 ± 
13.38 years. Fifty percent of patients were male. Patients’ 
clinical characteristics are shown in Table 2. White blood 
cell count ranged from 570 to 13.5×103 with the median 
of 139×103. The minimum and maximum blast count was 
153 and 9×103, respectively. The flow cytometry analysis 
showed that the most and the least patients were in M2 
and M3 subtypes with 40% and 10%, respectively. Thirty 
out of 40 patients were found to be leukemic CD34+ 
positive. 
Gene expression 
Comparison of WT-1, BAALC and ERG gene expressions in 
AML patients in pre- and post- chemotherapy phases
The gene expression of WT-1, BAALC and ERG decreased 
significantly in the post-chemotherapy phase. The median 
of WT-1, BAALC and ERG pre- and post- chemotherapy is 
shown in Figure 1. 
Correlation between WT-1, BAALC and ERG with CR 
There was an inverse significant correlation between 
post-chemotherapy expression of WT-1 and CR (r= 
-0.387, P=0.024). Moreover, the expression of BAALC was 
correlated inversely with CR before chemotherapy (r= 
-0.318, P = 0.046). There was no significant correlation 
between ERG and CR pre- and post-chemotherapy 
(P=0.464 and 0.781) (Table 3). 
Gene expressions in subtypes 
The expressions of WT-1, BAALC and ERG were 
categorized in the form of high (>median) and low (≤ 
median). Table 4 depicts the FAB classification in relation 
to low and high expression for WT-1, BAALC and ERG. 
The results showed that, all patients in subtype M3 had 
high expression of WT-1. Also, in subtype M2, 67% of the 
patients showed high expression of WT-1. However, there 
were no significant differences among subtypes of AML in 
terms of WT-1 expression (P =0.08). 
Regarding BAALC, 66.7% of subtype M5 were high 
expressers. In subtypes M2, the percentages of high and 
low expressions were similar. For ERG, 66.7% and 62.5% 
of subtype M1 and M2 were high expressers. There were 
no significant differences between AML subtypes in terms 
of ERG and BAALC expressions (P >0.05) (Table 4). 
Comparison of WT-1, BAALC and ERG expression in 
relation to CD34+ 
Table 4 represents the differences of WT-1, BAALC and 
Figure 1. WT-1, BAALC and ERG expressions in BM of AML patients 
in pre- and post-chemotherapy phases.
Table 2. Basic characteristics of patients
Characteristics Median (min, max)
Age 36.75 ± 13.38*
Sex (male) 20 (50%)
WBC count/L 135×103 (570-139×103)
Blast count /L 3525.50 (153.00- 90880.00)
Blast (%) 24.50 (7.00-71.00)
Platelet count 63 × 103 (13 ×103 – 575 ×103)
RBC 3.06 (2.27- 4.58)
HB 8.7 (6.8- 11.20)
MCV 92.75 (80.00 – 106.00)
Neutrophil 2.48 ×103 (210- 58.9 ×103)










* Mean ± SD.
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ERG expressions in AML patients with CD34 positive 
(CD34+) in comparison with CD34 negative (CD34-). 
There were no significant differences in WT-1 expressions 
between two groups. BAALC and ERG expressions were 
significantly higher in CD34+ AML patients (P <0.001 and 
0.028, respectively). 
Correlation between WT-1, BAALC and ERG expression 
and hematologic characteristics
The results showed that (Table 5), WT-1 expression had 
inverse and significant correlations with platelet and 
neutrophil counts (r= -0.349, P =0.037; r= -0.351, P =0.036, 
respectively). There was also a significant correlation 
between BAALC expression and blast count at baseline 
(r=0.337, P =0.034). Furthermore, ERG expression was 
inversely correlated with platelet count (r= -0.581, P 
<0.001).
Discussion 
In the present study, 35% of the patients reached CR at 
post-chemotherapy phase. WT-1, BAALC and ERG gene 
expressions in bone marrow decreased significantly after 
chemotherapy. The most reduction was observed in WT-1 
expression from 1.009 to 0.084. Furthermore, there was 
an inverse association between the expression of WT-1 
post- chemotherapy and CR. Parallel to our study, Ujj et 
al16 reported that CR was achieved in patients whose WT-1 
gene expression changed from positive to negative during 
therapy. They conclude that the affected level of WT-1 
expression after therapy could be a prognostic factor in 
AML patients. In line with that, previous studies reported 
that the ratio of WT-1 in pre- and post- chemotherapy 
phases was considered as a predictor of disease outcome in 
AML patients who have undergone “3+7” chemotherapy.20 
Moreover, in a study by Anderson et al it was shown that 
a 1 log reduction in WT-1 expression in one month of 
chemotherapy was significantly correlated with the overall 
survival; and the level of WT-1 in diagnosis was not found 
to be a prognostic marker in these patients.4 These results 
showed that early and deep reduction of WT-1 expression 
can be used as a useful marker for disease outcome 
in AML patients. The role of WT-1 in hematologic 
malignancies has not been clearly understood. Earlier 
studies have reported the involvement of WT-1 not only 
in proliferation but also in the inhibition of apoptosis 
in tumor cell cultures.21 Our findings showed that the 
standard chemotherapy was partially successful in WT-1 
reduction that was correlated with CR. Opposite to WT-1, 
our results depicted that BAALC expression at diagnosis 
was inversely correlated with CR. The expression of 
BAALC decreased significantly after chemotherapy, but 
the reduction was not as high as the reduction in WT-1. 
Table 3. Correlation between WT-1, BAALC and ERG expressions and 
complete remission pre- and post-chemotherapy
Complete Remission
Pre- chemotherapy Post- chemotherapy 
r P r P
WT-1 0.252 0.138 -0.387 0.024
BAALC -0.318 0.046 0.027 0.861
ERG 0.118 0.464 -0.045 0.781
Table 4. Comparison of WT-1, BAALC and ERG expression among AML subtypes and CD34
WT-1 expression BAALC expression ERG expression 
High expression Low expression  P* High expression Low expression  P High expression Low expression  P 
FAB classification 0.080 0.412 0.411
M1 2 (33.3%) 4 (66.7%) 2 (33.3%) 4 (66.7%) 4 (66.7%) 2 (33.3%)
M2 8 (66.7%) 4 (33.3%) 10 (62.5%) 6 (37.5%) 10 (62.5%) 6 (37.5%)
M3 4 (100%) 0 (0%) 2 (50.0%) 2 (50.0%) 2 (50.0%) 2 (50.0%)
M4 2 (25.0) 6 (75.0%) 2 (25.0%) 6 (75.0%) 2 (25.0%) 6 (75.0%)
M5 2 (33.3%) 4 (66.7%) 4 (66.7%) 2 (33.3%) 2 (33.3%) 4 (66.7%)
CD34 0.457 <0.001 0.028
Positive 14 (77.8%) 12 (66.7%) 20 (100%) 10 (50.0%) 18 (90.0%) 12 (60.0%)
Negative 4 (22.2%) 6 (33.3%) 0 (0%) 10 (50%) 2 (10.0%) 8 (40.0%)
* Chi-square test.
Table 5. Correlation between WT-1, BAALC and ERG expression and hematologic characteristics
 Platelet WBC  Blast count Neutrophil
r P r P r P r P
WT-1 -0.349 0.037 0.096 0.578 0.009 0.957 -0.351 0.036
BAALC -0.189 0.249 0.291 0.068 0.337 0.034 0.253 0.115
ERG -0.581 <0.001 0.066 0.687 0.167 0.304 -0.170 0.295
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No significant correlation between post- chemotherapy 
BAALC expression and CR was found. Former studies 
also found that high BAALC expression at diagnosis 
had negative prognostic effect in AML patients.8,22-24 
In a study by Soliman, et al9 there was no difference 
in BAALC expression pre- and post- chemotherapy 
which was in contrast of ours. However, in line with 
our findings, high BAALC expression was significantly 
correlated with lower CR.9 Baldus et al25 suggested that 
the overexpression of BAALC could determine patients’ 
resistance to treatment. However, in AML patients who 
have undergone allogeneic hematopoietic stem cell 
transplantation, BAALC expression had no prognostic 
effect.26 BAALC was found to block myeloid differentiation 
and promote leukemogenesis.12 Furthermore, in pediatric 
AML patients, BAALC and ERG expressions were shown 
to associate with low induction remission.27,28 BAALC 
overexpression was found in a group of genes which were 
identified as a high risk group for survival with MN1, 
SPARC, HOPX genes.22 
In our study, the levels of ERG decreased after 
treatment. There was no significant correlation between 
ERG expression and CR pre- and post- chemotherapy 
phases. In contrast, high ERG was associated with poor 
CR in the Soliman study.9 Also, Marcucci et al, in a 5.7 
year follow-up study, concluded that ERG expression 
could be an independent prognostic factor in AML 
patients.15 In a study of 50 AML patients, CR was different 
between low and high expression of ERG.29 Moreover, 
in a meta-analysis of seven studies, it was showed that 
high ERG expression was associated with lower CR and 
higher relapse in cytogenetically normal AML patients.14 
ERG was involved in cell differentiation, proliferation and 
apoptosis. It also plays a role in leukemogenesis as a fusion 
partner with the FUS gene in recurrent AML patients.30,31
Our analysis showed that all patients in subtype M3 
had high expression of WT-1 at diagnosis and the least 
percentage of the patents in WT-1 expression were M1 
and M5. Accordingly, in a study of forty-three adult 
AML patients, the highest and the lowest expressions of 
WT-1 were found in M3 and M5, respectively.4 However, 
similar to our study, no significant difference was found in 
WT-1 expressions among AML subtypes.4 In contrast, in 
a study in Mashhad, Iran, the highest percentage of WT-1 
expression was shown in subtype M1 and the lowest was 
in M6.19 In our study, there was no patient in M6 subtype. 
Highest expression of BAALC and ERG were observed 
in M5 and M1, respectively. There were also no significant 
differences among subtypes in terms of BAALC and 
ERG expressions at diagnosis. In line with our result, in 
an Egyptian study, the differences in BAALC and ERG 
expressions among AML subtypes were not significant.9 
Also, in this study, the number of patients in M1 was the 
highest in terms of BAALC expression and in M2 and M3 
in terms of ERG expression9 which was different from our 
study. In a study of Zhang et al,26 the M0 subtype had the 
highest expressions of BAALC and ERG in AML patients 
and the lowest BAALC expression was in M5 that was 
opposite to our study groups. 
We also compared the WT-1, BAALC, and ERG 
expressions in terms of CD34+. The findings showed that 
only BAALC had significantly higher expression in CD34+ 
patients which was similar to a study of Damiani et al8 on 
175 AML patients in Italy. In another study the expression 
of BAALC was higher in CD34+ patients with AML.32 
However, some studies found no significant difference 
in CD34+ between high and low expression groups 
of BAALC.29 There was also no significant difference 
between CD34+ and CD34- in terms of WT-1 expression 
in Anderson et al study4 that was similar to our results. 
Furthermore, WT-1 expression had significant 
correlations with platelet and neutrophil counts. Also, 
BAALC was significantly correlated with blast count. In a 
study by Zhou et al,33 a substantial amount of bone marrow 
blast counts were observed in AML patients who highly 
expressed BAALC compared to low-expressed ones. Also, 
high expression of BAALC was associated with increased 
blasts in Chinese AML patients.34 In contrast, a number of 
former studies found no significant correlation between 
BAALC expression and blast count.9,20,22
This study had some strengths and limitations. This is 
the first study that was conducted in North-West of Iran 
and the patients were selected from the referral hospital to 
which patients with diverse ethnics referred. However, due 
to limited financial support, we were unable to evaluate 
the mutations that are molecular abnormalities in AML 
patients. Also, the small number of patients was another 
limitation for our study. Future studies with large sample 
size and longer duration are warranted. 
Conclusion
In conclusion, we found a significant decrease in WT-1, 
BAALC, and ERG expressions after chemotherapy; the 
decline in WT-1 expression was significantly correlated 
with CR. Also, BAALC overexpression at diagnosis could 
be a prognostic marker in AML patients. 
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